

# Gaucher Disease: The Evolving Big Picture

Please join us for a 2-Part CE Satellite Symposium

Tuesday, February 6

11:45 AM – 12:45 PM

Grand Hall AB



## Part I: Unmet Needs and Redefining the GD Spectrum

### PROGRAM OVERVIEW:

Although Gaucher disease is one of the most widely known of the lysosomal diseases and treatments are available, there is still so much that needs to be addressed. This 2-part CE satellite session focuses on key issues with Gaucher disease (GD) that require ongoing discussion, research and attention. The goal is to raise awareness of the current challenges in GD diagnosis and lifelong management, and provide a forum for discussion for future changes.

### PART I:

The **first part** addresses the role of inflammation in GD, the evolution of the natural history of GD including the need to redefine beyond types I, II and III, and how to manage neuronopathic GD, followed by a panel discussion.

### PART II:

The **second part** of this session covers the challenges and opportunities for newborn screening (NBS), what to do after GD is identified on NBS, what discussions need to occur during management of GD during pregnancy, and concludes with a panel discussion.

11:45 AM	Welcome and Introduction	Uma Ramaswami
11:48 AM	Perspectives on the Delineation of Gaucher Disease Variants	Greg Grabowski
12:00 PM	Glucocerebrosidase Dysfunction: Pathobiology Beyond Lipid Storage	Reena Kartha
12:15 PM	Do We Really Know How to Manage Neuronopathic Gaucher Disease	Ozlem Goker-Alpan
12:30 PM	Wrap Up Day I; Set the Stage for Part II	Uma Ramaswami
12:35 PM	Q&A and Discussion	Faculty
12:45 PM	Adjourn	

### TARGET AUDIENCE:

This activity is intended for healthcare professionals involved in the screening, diagnosis, management, and treatment of lysosomal diseases affecting both children and adults, with research and clinically relevant information geared specifically to the following professionals: medical and clinical geneticists; genetic counselors; pediatricians; neurologists; psychologists; nurse practitioners; physician assistants; and patient advocates.

There is no additional fee to attend this satellite symposium.

# Gaucher Disease: The Evolving Big Picture

## LEARNING OBJECTIVES:

1. Delineate the potential issues in diagnosing GD, follow-up testing, and initiation of therapy.
2. Discuss recent guidelines for identification and management of GD.
3. Outline appropriate strategies for management based on the patient's stage in life, including newborns, pediatrics, elderly patients and management during pregnancy.
4. Define the emerging treatments for Gaucher disease, differentiating for whom and when these treatments should be considered.
5. Elucidate the role of inflammation and the importance of biomarkers for monitoring therapies that address inflammation.
6. Identify biomarkers of neuronal disease and apply them in monitoring progression in patients.
7. Discuss the evolution of the natural history of GD and initiate discussions on redefining Gaucher disease beyond types I, II and III.
8. Define the evolving approach in managing type 3 Gaucher disease, including recent therapeutic advances.

## FACULTY:



Uma Ramaswami, FRCPCH, MD (Chair)  
Royal Free London  
NHS Foundation Trust  
London, United Kingdom



Reena Kartha, MS, PhD  
University of Minnesota  
Minneapolis, MN, United States



Gregory A. Grabowski, MD  
Cincinnati Children's Hospital  
Research Foundation  
Cincinnati, OH, United States



Ozlem Goker-Alpan, MD  
Lysosomal and Rare Disorders  
Research & Treatment Center, Inc.  
Fairfax, VA, United States



## CE ACCREDITATION:

This activity is jointly provided by Postgraduate Institute for Medicine and Saterdalen & Associates, LLC.

### Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Saterdalen & Associates, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours.

Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 2.0 contact hours.



## CE CREDIT & FACULTY DISCLOSURES

Instructions to obtain CE credit or a Certificate of Attendance for this activity are available using the QR code. Faculty disclosures may also be downloaded at this link.

This activity is not available for CEU credits for Genetic Counselors.

*Participants must attend both days to receive 2.0 hours of credit.*

## GRANT SUPPORT

This activity is supported by an independent educational grant from Takeda Pharmaceuticals, U.S.A., Inc.

**Eligibility:** Registration for *WORLDSymposium 2024* and an official name badge are required to attend this satellite symposium.

*WORLDSymposium*<sup>™</sup> has reviewed and approved this Satellite Symposium as appropriate for presentation as an independent educational activity held in conjunction with *WORLDSymposium 2024*. This Satellite Symposium is not part of the official *WORLDSymposium* program, and *WORLDSymposium* does not approve or endorse any commercial products or services discussed during the Satellite Symposium or offered for sale by the corporate supporter of the Satellite Symposium. This Satellite Symposium is not approved for CE by *WORLDSymposium*. This Satellite Symposium is approved for CE credit by the Postgraduate Institute for Medicine.